The innovations include a new pre-eclampsia test for pregnant women and an advanced blood test for heart attack diagnosis.
News
Sales Awards finalists give their thoughts on the competition
The prestigious PharmaTimes Sales Awards has been recognised by finalists and winners on its highly beneficial and rewarding challenges.
Death risk from sepsis lasts up to five years
The research, published in JAMA Network Open today, found that 15% of sepsis survivors died within a year of leaving hospital.
AbbVie, Roche present positive Venclyxto results at ASCO
Venclyxto is a first-in-class targeted medicine designed to selectively bind and inhibit the B-cell lymphoma-2 protein.
Lynparza ASCO success continues with positive ovarian cancer results
The treatment achieved a 72% objective response rate in patients with previously treated germline BRCA1/2-mutated advanced ovarian cancer.
FDA ‘yes’ for Emgality in cluster headache
In a trial, patients taking Emgality experienced 8.7 fewer weekly cluster headache attacks than they did at baseline.
Categories available for all experience levels in the 2019 Marketer of the Year competition
There are a broad range of categories in the PharmaTimes Marketer of the Year competition, designed to cover all sectors and suitable for all experience levels.
New late stage prostate cancer technology available in UK
The technology, called Theranostics, provides a personalised approach to treatment and diagnosis in prostate cancer.
Bluebird bags EU conditional marketing authorisation for Zynteglo
The authorisation for the inherited blood disorder marks bluebird’s first ever drug approval.
Thousands more GP staff recruited across England
The recruitment drive means that there are now 7,302 more full time equivalent health professionals working in primary care.
Promising early results for BMS’ investigational HCC study
The company are “encouraged by these early results”, as liver cancer affects over 5,700 new patients in the UK each year.
Janssen presents positive Darzalex results at ASCO
The drug showed non-inferior efficacy and a significantly higher complete response rate in two different trials.
Novartis’ Kisqali hits endpoints in Phase III breast cancer trial
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer.
‘Unprecedented’ results in AZ’ late-stage Lynparza trial
The results were announced at the 2019 ASCO meeting.
GP surgery closures hit ‘all-time-high’ last year
The closures are directly affecting smaller practices, with nine out of 10 practices that closed serving fewer than 5,000 patients.
